California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Gold and Silver Prices Dip as Markets Await Key U.S. Economic Data 
Asian Stocks Slide as AI Valuation Fears and BOJ Uncertainty Weigh on Markets 
Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Fed Near Neutral Signals Caution Ahead, Shifting Focus to Fixed Income in 2026 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Bank of Korea Downplays Liquidity’s Role in Weak Won and Housing Price Surge 
COVID-19 vaccines are expensive but a new alternative is coming and this will cut the costs. A division of the Japanese pharma company, Mitsubishi Tanabe Pharma Company, has developed the world’s first plant-based coronavirus vaccine and is looking to launch it soon.
The Medicago biopharmaceutical company that is owned by Mitsubishi Tanabe said that its new COVID-19 vaccine would be cheaper and easier to move compared to the conventional types since this is plant-based. It was also mentioned that Medicago is also backed by the Marlboro producer, Philip Morris International.
According to the Financial Times, the head of Mitsubishi Tanabe Pharma’s vaccine business development, Toshifumi Tada, revealed that Medicago would be applying for approval of its plant-based vaccine in Canada by the end of this year.
With its successful development of the alternative COVID-19 vaccine, the Osaka headquartered pharmaceutical firm is expecting global demand for the product. The company also believes that the demand will remain strong since medical professionals continue to detect new strains of the highly contagious coronavirus.
It was noted that no single plant-based vaccine had been approved yet for use in humans, but supporters of the new technology stated that such a type of vaccine is very appealing since plant leaves grow quickly. This fact alone makes the production process cheaper and faster.
Traditional flu vaccines usually take around eight to 12 months to produce but Medicago’s plant-based alternative will only take up five to eight weeks. Plus, the vaccines do not need to be deep-frozen while being transported, as they can be stored at 2C to 8C temperatures.
“Compared to alternative production systems, our proprietary plant-based manufacturing platform has many advantages, including faster lead time, scalability, and versatility,” Medicago’s senior director of scientific and medical affairs, Nathalie Charland, said via the Nature Research Journal. “The rapid nature of our vaccine and therapeutic protein production unlocks many potential ways in which we can better respond to infectious diseases and public health challenges.”
Meanwhile, Medicago will partner with GlaxoSmithKline for the phase 3 trial for its plant-based vaccine in Canada, U.S., the U.K, Mexico, Brazil, and Argentina. The trial is said to involve 24,000 subjects in all.
